These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 33479914

  • 1. Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [99mTc]-(I)-Tricarbonyl Complex.
    Facca VJ, Al-Saden N, Ku A, Reilly RM.
    Mol Imaging Biol; 2021 Aug; 23(4):495-504. PubMed ID: 33479914
    [Abstract] [Full Text] [Related]

  • 2. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with 99mTc(I) Tricarbonyl Complex.
    Ku A, Chan C, Aghevlian S, Cai Z, Cescon D, Bratman SV, Ailles L, Hedley DW, Reilly RM.
    Mol Pharm; 2019 Aug 05; 16(8):3559-3568. PubMed ID: 31242384
    [Abstract] [Full Text] [Related]

  • 3. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing 89Zr - In vitro stability and in vivo microPET/CT imaging studies in NOD/SCID mice with HER2-positive SK-OV-3 human ovarian cancer xenografts.
    Cho H, Al-Saden N, Lam H, Möbus J, Reilly RM, Winnik MA.
    Nucl Med Biol; 2020 Aug 05; 84-85():11-19. PubMed ID: 31931305
    [Abstract] [Full Text] [Related]

  • 4. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments.
    Tang Y, Scollard D, Chen P, Wang J, Holloway C, Reilly RM.
    Nucl Med Commun; 2005 May 05; 26(5):427-32. PubMed ID: 15838425
    [Abstract] [Full Text] [Related]

  • 5. 64Cu-Labeled Trastuzumab Fab-PEG24-EGF Radioimmunoconjugates Bispecific for HER2 and EGFR: Pharmacokinetics, Biodistribution, and Tumor Imaging by PET in Comparison to Monospecific Agents.
    Kwon LY, Scollard DA, Reilly RM.
    Mol Pharm; 2017 Feb 06; 14(2):492-501. PubMed ID: 28049295
    [Abstract] [Full Text] [Related]

  • 6. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with 89Zr-Labeled Trastuzumab-DM1: A Comparison with 89Zr-Labeled Trastuzumab.
    Al-Saden N, Lam K, Chan C, Reilly RM.
    Mol Pharm; 2018 Aug 06; 15(8):3383-3393. PubMed ID: 29957952
    [Abstract] [Full Text] [Related]

  • 7. MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using ¹¹¹In-labeled bispecific radioimmunoconjugates.
    Razumienko E, Dryden L, Scollard D, Reilly RM.
    Breast Cancer Res Treat; 2013 Apr 06; 138(3):709-18. PubMed ID: 23525982
    [Abstract] [Full Text] [Related]

  • 8. Development and preclinical studies of 64Cu-NOTA-pertuzumab F(ab')2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT.
    Lam K, Chan C, Reilly RM.
    MAbs; 2017 Jan 06; 9(1):154-164. PubMed ID: 27813707
    [Abstract] [Full Text] [Related]

  • 9. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ, Chen JC, Cai Z, Chan C, Reilly RM.
    J Nucl Med; 2016 Mar 06; 57(3):444-52. PubMed ID: 26429962
    [Abstract] [Full Text] [Related]

  • 10. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
    Razumienko EJ, Scollard DA, Reilly RM.
    J Nucl Med; 2012 Dec 06; 53(12):1943-50. PubMed ID: 23096164
    [Abstract] [Full Text] [Related]

  • 11. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe 99mTc-HYNIC-H6F in Breast Cancer Mouse Models.
    Li L, Wu Y, Wang Z, Jia B, Hu Z, Dong C, Wang F.
    J Nucl Med; 2017 May 06; 58(5):821-826. PubMed ID: 28104744
    [Abstract] [Full Text] [Related]

  • 12. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
    McLarty K, Cornelissen B, Cai Z, Scollard DA, Costantini DL, Done SJ, Reilly RM.
    J Nucl Med; 2009 Aug 06; 50(8):1340-8. PubMed ID: 19617342
    [Abstract] [Full Text] [Related]

  • 13. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
    Orlova A, Nilsson FY, Wikman M, Widström C, Ståhl S, Carlsson J, Tolmachev V.
    J Nucl Med; 2006 Mar 06; 47(3):512-9. PubMed ID: 16513621
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts.
    Marquez BV, Ikotun OF, Zheleznyak A, Wright B, Hari-Raj A, Pierce RA, Lapi SE.
    Mol Pharm; 2014 Nov 03; 11(11):3988-95. PubMed ID: 25058168
    [Abstract] [Full Text] [Related]

  • 15. A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT.
    Chan C, Scollard DA, McLarty K, Smith S, Reilly RM.
    EJNMMI Res; 2011 Aug 17; 1(1):15. PubMed ID: 22214307
    [Abstract] [Full Text] [Related]

  • 16. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 111In and 177Lu-An EGFR-Targeted Theranostic for Pancreatic Cancer.
    Aghevlian S, Lu Y, Winnik MA, Hedley DW, Reilly RM.
    Mol Pharm; 2018 Mar 05; 15(3):1150-1159. PubMed ID: 29314858
    [Abstract] [Full Text] [Related]

  • 17. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and In vivo Performance of 89Zr-DFO-Pertuzumab.
    Vivier D, Fung K, Rodriguez C, Adumeau P, Ulaner GA, Lewis JS, Sharma SK, Zeglis BM.
    Theranostics; 2020 Mar 05; 10(4):1746-1757. PubMed ID: 32042334
    [Abstract] [Full Text] [Related]

  • 18. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).
    Zhang J, Zhao X, Wang S, Wang N, Han J, Jia L, Ren X.
    Nucl Med Biol; 2015 Jun 05; 42(6):541-6. PubMed ID: 25735223
    [Abstract] [Full Text] [Related]

  • 19. Preparation and characterization of 99mTc(CO)3-BPy-RGD complex as alphav beta3 integrin receptor-targeted imaging agent.
    Zhang X, Chen X.
    Appl Radiat Isot; 2007 Jan 05; 65(1):70-8. PubMed ID: 17011200
    [Abstract] [Full Text] [Related]

  • 20. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
    Ahlgren S, Wållberg H, Tran TA, Widström C, Hjertman M, Abrahmsén L, Berndorff D, Dinkelborg LM, Cyr JE, Feldwisch J, Orlova A, Tolmachev V.
    J Nucl Med; 2009 May 05; 50(5):781-9. PubMed ID: 19372467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.